AnaptysBio Inc ANAB:NASDAQ

Last Price$44.73NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/17/19

Today's Change-0.53(1.17%)
Bid (Size)$44.67 (32)
Ask (Size)$44.73 (35)
Day Low / High$44.25 - 46.34
Volume494.3 K

View Biotechnology IndustryPeer Comparison as of 09/17/2019


AnaptysBio Inc ( NASDAQ )

Price: $44.73
Change: -0.53 (1.17%)
Volume: 494.3 K
4:00PM ET 9/17/2019

Veracyte Inc ( NASDAQ )

Price: $26.11
Change: -0.06 (0.23%)
Volume: 497.7 K
4:00PM ET 9/17/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Editas Medicine Inc ( NASDAQ )

Price: $25.76
Change: +0.01 (0.04%)
Volume: 348.4 K
4:00PM ET 9/17/2019

Sangamo Therapeutics Inc ( NASDAQ )

Price: $11.16
Change: -0.14 (1.24%)
Volume: 759.6 K
3:59PM ET 9/17/2019

Read more news Recent News

AnaptysBio CFO to Step Down, General Counsel to Take Role on Interim Basis
4:56PM ET 8/19/2019 MT Newswires

AnaptysBio (ANAB) said in a SEC filing CFO Dominic Piscitelli will leave on Sept 9, and General Counsel Eric Loumeau will become interim CFO. Price: 48.10,...

Analyst Actions: Credit Suisse Cuts AnaptysBio's Price Target to $75 From $79, Reiterates Neutral Rating
11:03AM ET 8/09/2019 MT Newswires

AnaptysBio (ANAB) has average rating among analysts of buy, with an average price target of $117. Price: 50.70, Change: -1.79, Percent Change: -3.41 ...

Close Update: Major US Market Indexes Post Advances for Week Even With Friday Slip
4:32PM ET 6/21/2019 MT Newswires

Major market indexes dipped slightly Friday but managed to post solid gains for the week as the S&P 500 slipped, off its record closing high, from the...

Mid-Day Report: US Stocks Fluctuated as Fed Officials Fan Dovish Flames; Oil Climbs as Iran Tensions Ease But Remain Combustible
1:50PM ET 6/21/2019 MT Newswires

US stocks were mixed following Thursday's gains as Federal Reserve officials fanned dovish signals from the Central Bank and after a closely watched...

Company Profile

Business DescriptionAnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA. View company web site for more details
Address10421 Pacific Center Court
San Diego, California 92121
Number of Employees78
Recent SEC Filing08/20/20194
President, Chief Executive Officer & DirectorHamza Suria
Chief Financial Officer & General CounselEric J. Loumeau
Chief Medical OfficerMarco Londei
Vice President & ControllerDavid McKeon

Company Highlights

Price Open$45.50
Previous Close$45.26
52 Week Range$38.53 - 110.00
Market Capitalization$1.2 B
Shares Outstanding27.0 M
SectorHealth Technology
Next Earnings Announcement11/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.00
Beta vs. S&P 500N/A
Revenue$5.0 M
Net Profit Margin-789.92%
Return on Equity-16.61%

Analyst Ratings as of 08/17/2019

Consensus RecommendationConsensus Icon
Powered by Factset